Another recent study has found that the well-characterized antitumor agent SBF-1 can selectively bind to the AR-DBD and block the transcription of AR target genes, and has been proven to repress prostate cancer growth both in vitro and in vivo [134]. This evidence concerns the gene AR and Familial prostate cancer.